Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
7 authors.
Marissa F FarinasDepartment of Psychiatry, School of Medicine, University of Pittsburgh, 3811 O'Hara Street, Pittsburgh, PA, 15213, USA.
Yijun ChenDepartment of Chemistry, University of Pittsburgh, Pittsburgh, PA, 15213, USA.
Xuemei ZengDepartment of Psychiatry, School of Medicine, University of Pittsburgh, 3811 O'Hara Street, Pittsburgh, PA, 15213, USA.
Michel N NafashDepartment of Psychiatry, School of Medicine, University of Pittsburgh, 3811 O'Hara Street, Pittsburgh, PA, 15213, USA.ORCID 0009-0005-6953-075X
Ann D CohenDepartment of Psychiatry, School of Medicine, University of Pittsburgh, 3811 O'Hara Street, Pittsburgh, PA, 15213, USA.
Oscar I LopezDepartment of Psychiatry, School of Medicine, University of Pittsburgh, 3811 O'Hara Street, Pittsburgh, PA, 15213, USA.
Thomas K KarikariDepartment of Psychiatry, School of Medicine, University of Pittsburgh, 3811 O'Hara Street, Pittsburgh, PA, 15213, USA.ORCID 0000-0003-1422-4358
Funding
Vascular Moderators of the Impact of Alzheimer's Pathology in the Young-OldP01AG025204 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI HOWARD J AIZENSTEIN, Ann D. Cohen · 2005 to 2026
$56.5M
Longitudinal multicenter head-to-head harmonization of tau PET tracersR01AG073267 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BAKER, SUZANNE L, PASCOAL, THARICK · 2021 to 2025
$41.1M
Research Education ComponentP30AG066468 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI C. Elizabeth Shaaban · 2020 to 2026
$29.4M
Plasma brain-derived tau: a novel Alzheimer’s disease-type neurodegeneration biomarker with potential to complete the AT(N) scheme in bloodR01AG083874 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Thomas K Karikari · 2023 to 2026
$14.5M
The RAW Brain - The Effect of Rumination, Anxiety and Worry on Aging and Dementia RiskR01MH108509 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Carmen Andreescu · 2016 to 2026
$10.6M
Alzheimer Diagnosis in older Adults with Chronic Conditions ADACC NetworkU24AG082930 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Nicole R. Fowler, Thomas K Karikari · 2023 to 2026
$7.3M
Examining the Persistence of Neurocognitive Benefits of ExerciseR01AG083156 · NIA · ADVENTHEALTH ORLANDO · PI ERICKSON, KIRK I · 2023 to 2025
$6.8M
Analytical characterization and validation of blood-biomarkers for monitoring TBI evolutionU01NS131740 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Ramon Diaz-Arrastia, Ava M. Puccio · 2024 to 2026
$4.7M
Roles of Gray Matter Brain Aging and Small Vessel Disease in AD PathophysiologyR01AG025516 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI HOWARD J AIZENSTEIN, Victor Luis Villemagne · 2024 to 2026
$4.4M
Head-to-head comparisons of high-performance plasma phospho-tau epitopes for the detection of Alzheimer's diseaseR01AG075336 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Tharick Pascoal · 2022 to 2026
$3.7M
Myosteatosis, Cognition, and Blood Biomarkers of Alzheimer's Disease in Persons of African AncestryRF1AG077474 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MILJKOVIC, IVA, ROSANO, CATERINA · 2022 to 2024
$3.6M
Brain CHEC-AC (Brain and Cognitive Health Equity Campaign for Allegheny County)U01NS141777 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JENNIFER Hagerty LINGLER, C. Elizabeth Shaaban · 2024 to 2026
methodsWe compared its performance on 43 matched serum-plasma pairs from a memory clinic cohort.
resultsThe panel reproducibly quantified 124 targets (mean CV=4.9%) with high detectability (mean=95.7%). Serum-plasma correlations were strong (ρ>0.7) for 79 targets. 48 targets had significant NPQ differences, with 32 higher in plasma. Plasma had more erythrocyte-enriched proteins (HBA1, PGK1, SOD1, PRDX6), while serum had more platelet-derived proteins (CD40LG, BDNF, VEGFA, Aβ40). For classical AD biomarkers, serum-plasma correlations were stronger for p-tau, GFAP, and NfL (ρ>0.9) than for Aβ targets (ρ=0.594-0.785). Tau levels were higher in plasma; GFAP and NfL were similar, and Aβ peptides were mixed. Twelve targets, along with p-tau217/Aβ42, were linked to AD diagnosis, with plasma generally showing stronger effects. DISCUSSION: Our results support serum use but suggest plasma performs better for AD using this panel.
Indexed as
Alzheimer’s diseaseblood-based biomarkersNULISASeq™ CNS Disease Panelserum vs. plasma
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Plasma vs. serum: which is better for proteomic blood biomarker analysis? Evaluation of the novel NULISA platform. · full record | OpenQuestion